You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 131 No. 6, June 1995 TABLE OF CONTENTS
  Archives
  •  Online Features
  The Cutting Edge
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (12)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Addition of Rifampin to Conventional Therapy for Recurrent Furunculosis

Diane M. Hoss, MD; Henry M. Feder, Jr, MD

Arch Dermatol. 1995;131(6):647-648.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

REPORT OF A CASE

A 33-year-old man presented to the University of Connecticut Health Center, Farmington, because of recurrent ''boils'' on his face. During the prior 5 years, Staphylococcus aureus, susceptible to cloxacillin and cephalexin, was recovered from the boils. He received multiple courses of oral antibiotics, but facial ''boils'' continued to develop, both while receiving and not receiving therapy. When first seen, the patient had two facial furuncles. Treatment with cloxacillin (250 mg four times daily), topical chlorhexidine washes, and nightly applications of intranasal mupirocin ointment was effective initially, but the lesions recurred while he was still receiving this therapy. The oral antibiotic was changed to cephalexin (500 mg twice daily). Despite this therapy, new facial furuncles developed over the next several months.

THERAPEUTIC CHALLENGE

Treatment of persistent or recurrent furunculosis caused by S aureus.

SOLUTION

Cephalexin therapy (500 mg twice daily) was continued, and rifampin therapy (300 mg . . . [Full Text PDF of this Article]


Author Affiliations

University of Connecticut Health Center, Farmington



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.